Hiroya Tamai
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Assessment of drug levels as a biomarker in rheumatoid arthritis.
Journal: EULAR rheumatology open
Published: June 29, 2026
The progression of initial symptoms and its relationship with the clinical course in adult-onset Still's disease: from the KEIO-AOSD cohort.
Journal: EULAR rheumatology open
Published: June 29, 2026
Association of genetic variants with extravascular complications and cytokine production in Takayasu arteritis: a cross-sectional study.
Journal: Rheumatology advances in practice
Published: May 08, 2025
Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study.
Journal: Clinical and experimental rheumatology
Published: April 14, 2025
Achievement and Usefulness of Intermediate Treatment Targets for Still Disease Proposed by the European Alliance of Associations for Rheumatology and the Paediatric Rheumatology European Society.
Journal: The Journal of rheumatology
Published: March 17, 2025
1 mg/day or 10 mg/week? Folic acid supplementation with methotrexate in rheumatoid arthritis.
Journal: Modern rheumatology
Published: January 04, 2025
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
Journal: Annals of the rheumatic diseases
Published: July 01, 2024
Tocilizumab discontinuation after remission achievement in patients with adult-onset Still's disease.
Journal: Rheumatology (Oxford, England)
Published: December 19, 2023
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)
Published: October 11, 2023
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.
Journal: The Lancet. Rheumatology
Published: December 05, 2022
Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs.
Journal: Clinical rheumatology
Published: July 29, 2022
Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study.
Journal: PloS one
Published: April 19, 2022
Last Updated: 09/26/2026